ArticleDiabetology & metabolic syndrome2025
Evaluation of a management platform for extended care of type 2 diabetes.
Article in Diabetology & metabolic syndrome, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Initial treatment for uncontrolled type 2 diabetes: A clinical trial comparing basal insulin and modified-release gliclazide.Caspian journal of internal medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThis study aims to evaluate the efficacy of a diabetes chronic disease management platform in extended care for patients with diabetes.
methodsA cohort of 150 patients with type 2 diabetes (mean age, 51 years) were selected and randomly assigned to an observation group and a control group, each comprising 75 participants, from September 2023 to September 2024. The control group received standard extended care, while the observation group received extended care integrated with the diabetes chronic disease management platform. The two groups were compared in terms of blood glucose levels, emotional state, self-management ability, and quality of life at discharge and three months after the intervention. Additionally, the incidence of hypoglycemia and hospital readmission within three months after discharge were recorded and analyzed.
resultsThree months after the intervention, both groups exhibited reductions in fasting blood glucose, 2-hour postprandial blood glucose, glycated hemoglobin, and scores on the Self-Rating Anxiety Scale and Self-Rating Depression Scale compared to discharge levels. However, the observation group had significantly lower values than the control group (p < 0.05). Scores on the Summary of Diabetes Self-Care Activities decreased in both groups compared to discharge levels, but the observation group had relatively higher scores (p < 0.05). Scores on the General Quality of Life Inventory-74 increased in both groups compared to discharge, with the observation group demonstrating significantly higher scores across all dimensions (p < 0.05). Additionally, the incidence rates of hypoglycemia and hospital readmission were lower in the observation group than in the control group (p < 0.05).
conclusionThe diabetes chronic disease management platform improves the effectiveness of extended care interventions in managing blood glucose levels, emotional state, self-management ability, and quality of life in patients with diabetes, while also reducing the risk of hypoglycemia and hospital readmission after discharge.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.